- Molecular NameRitonavir
- SynonymAbbott 84538; ritonavir
- Weight720.96
- Drugbank_IDDB00503
- ACS_NO155213-67-5
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)4.81
- pkaN/A
- LogD (pH=7, predicted)4.81
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-6.28
- LogSw (predicted, AB/LogsW2.0)0.02
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors4
- No.of HBond Acceptors11
- No.of Rotatable Bonds18
- TPSA202.26
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.
- Absorption_valueN/A
- Absorption (description)Absolute bioavailability unknown (>60% absorbed); food elicits a 15% increase in oral AUC for capsule formulation.
- Caco_2N/A
- Bioavailability70.0
- Protein binding98.5
- Volume of distribution (VD)1.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmRitonavir is extensively metabolized primarily by CYP3A4.
- Half life3~5 h
- Excretionmostly fecal
- Urinary Excretion3.5
- Clerance1.2 ml/min/kg (SD) or 2.1 ml/min/kg (MD)
- ToxicityHuman experience of acute overdose with ritonavir is limited. One patient in clinical trials took ritonavir 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.
- LD50 (rat)N/A
- LD50 (mouse)N/A